Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease Moderate
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
This is a phase II, randomised, double blind, placebo controlled, complete block, three way crossover study to investigate treatment with nebulised RPL554 and tiotropium together in patients with moderate to severe chronic…
- Trial name
- NCT03028142
- Testing
- 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium
- Volunteers
- 30 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Cardiac Safety Study
- Trial name
- CARSAF (NCT01584505)
- Testing
- CHF1535 + CHF5992 dose 1 BID, CHF1535 + CHF5992 dose2 BID, CHF1535 daily dose
- Where
- 6 sites in Bulgaria, Germany and 4 more
- Volunteers
- 191 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cachexia, Chronic Obstructive Pulmonary Disease
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients
To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and…
- Conditions
- Cachexia, Chronic Obstructive Pulmonary Disease, Chronic Heart Failure
- Trial name
- NCT00852020
- Testing
- oral nutrition supplement, food for special medical purposes
- Where
- 4 sites in Germany, Poland
- Volunteers
- 60 people
- Sponsor
- Fresenius Kabi
Moderate to Severe COPD
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Columbus (NCT00690482)
- Testing
- AZD1981
- Where
- 21 sites in Bulgaria, Denmark and 3 more
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
It is hypothesised that there is a difference between the uptake of a radioactive substance ([18F]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
- Trial name
- NCT00472264
- Testing
- PET imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
The objective of this non-interventional, observational study is to assess whether changing Chronic Obstructive Pulmonary Disease (COPD) patients from a dry powder inhaler (HandiHaler®) to a soft mist inhaler (Respimat®), without…
- Trial name
- NIS PIRATE (NCT05362487)
- Testing
- Spiriva® Respimat®, Spiriva® HandiHaler®, Tiotropium bromide
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of Remote Physiologic Monitoring (RPM) on Outcomes in COPD Patients
This pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of COPD subjects started on remote physiologic monitoring (RPM) at a large, outpatient pulmonary practice.
- Trial name
- NCT05518981
- Testing
- Respiratory Remote Patient Monitor (Spire Health Tag)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Spire, Inc.
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment…
- Trial name
- NCT02085798
- Testing
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
- Where
- 50 sites in Spain
- Volunteers
- 503 people
- Sponsor
- Celgene
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously…
- Trial name
- NCT01644734
- Testing
- Spiriva HandiHaler
- Where
- 247 sites in Poland
- Volunteers
- 1,328 people
- Sponsor
- Boehringer Ingelheim
COPD, COPD - Chronic Obstructive Pulmonary Disease
Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients
The goal of this clinical trial is to test a device called "ROAM" that is being developed to see how patients with chronic obstructive pulmonary disease (COPD) use oxygen therapy over a long period of time.
- Trial name
- ROAM (NCT06874101)
- Testing
- Activated ROAM System with User Feedback
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Barron Associates, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Spiriva® Assessment of FEV1 (SAFE)
The objective of this trial is to evaluate whether the effect of one year (48 weeks) treatment with inhaled tiotropium bromide (Spiriva® - 18 µg once daily) on the change in trough FEV1, compared to placebo in patients with COPD…
- Trial name
- NCT00277264
- Testing
- Tiotropium (Spiriva®)
- Where
- 96 sites in Canada
- Volunteers
- 914 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.
- Trial name
- NCT01555099
- Testing
- AZD5423, Budesonide
- Where
- 44 sites in Bulgaria, France and 6 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)
A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.
- Trial name
- NCT00482235
- Testing
- MK0359
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to identify demographic and non-spirometric clinical features predictive of the asthma-COPD overlap population.
- Trial name
- NCT02302417
- Testing
- Spirometry, ACOS clinical questionnaire
- Where
- 42 sites in United States, Argentina and 3 more
- Volunteers
- 1,215 people
- Sponsor
- GlaxoSmithKline
Stable COPD Patients
Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study
This is a multi-country, multicentre, observational prospective data collection cross sectional study of patients with stable COPD in Latin America.
- Trial name
- LASSYC (NCT02789540)
- Where
- 6 sites in Argentina, Chile and 4 more
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.